/Investor DB

Viking Global Investors — 2017 Investments

3 investments dated 2017 · listed companies and verified rows first · show all

Deciphera PharmaceuticalsinMay 2017

Develops selective kinase inhibitors for cancer (QINLOCK); acquired by Ono Pharmaceuticals in 2024.

BiotechWaltham, US

Daniel F. Flynn, Ph.D.(Executive Officer)Oliver Rosen, M.D.(Executive Officer)inThomas Kelly(Executive Officer)Michael Taylor(Executive Officer, Director)in

BoardMichael Ross(Director)Liam Ratcliffe, M.D., Ph.D.(Director)

Co-investorsFrazier Life SciencesViking GlobalREDMILE

Impossible Foodsimpossiblefoods.comin𝕏Aug 2017 · $75M

Impossible Foods produces plant-based meat alternatives, including beef, pork, chicken, and sausage products designed to replicate the taste, nutrition, and cooking properties of conventional animal meat.

ConsumerFoodTechHealthtechRedwood City, US

Pat Brown(Founder)inDavid Lee(Executive Officer)inPeter McGuinnessinPatrick O. Brown(Founder)in

BoardBart Swanson(Director)inSamir Kaul(Director)in

Co-investors1435 CapitalAliya Capital PartnersAllied Venture PartnersAngelDAOBlue Horizon CorporationBVP Investors+34 more

Vets First Choicevetsfirstchoice.cominJul 2017 · $223M

Covetrus provides software and pharmacy solutions for veterinary practices, including an integrated platform that manages prescription workflows, online pharmacy storefronts with home delivery, and compounded medication services.

HealthtechMedical DevicesSaaS

Co-investorsHarbor Light Capital PartnersMountain Group CapitalBorealis VenturesClayton Dubilier & RiceHLM Investment PartnersRock Springs Capital+1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.